Enhabit Inc. logo

Enhabit Inc. (EHAB)

Market Closed
14 May, 20:00
NYSE NYSE
$
13. 80
+0.01
+0.07%
$
706.91M Market Cap
- P/E Ratio
- Div Yield
652,845 Volume
0.25 Eps
$ 13.79
Previous Close
Add Transaction
Day Range
13.79 13.81
Year Range
6.47 14.22
Want to track EHAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EHAB closed Thursday higher at $13.8, an increase of 0.07% from Wednesday's close, completing a monthly increase of 0.36% or $0.05. Over the past 12 months, EHAB stock gained 49.19%.
EHAB is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NYSE (USD).

EHAB Chart

People also search for

MD
Pediatrix Medical Group, Inc.
$ 21.84
+0.37%
HNI
Hni Corporation
$ 30.17
-1.89%
Nuvation Bio Inc.
$ 4.72
-3.67%
AGL
Agilon Health Inc.
$ 82.7
-4.67%
Teladoc Health Inc.
$ 7.09
-5.91%
Fast-paced Momentum Stock Enhabit (EHAB) Is Still Trading at a Bargain

Fast-paced Momentum Stock Enhabit (EHAB) Is Still Trading at a Bargain

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks | 2 weeks ago
Enhabit (EHAB) Upgraded to Buy: Here's Why

Enhabit (EHAB) Upgraded to Buy: Here's Why

Enhabit (EHAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 3 weeks ago
Enhabit, Inc. (NYSE:EHAB) Receives Consensus Rating of “Hold” from Brokerages

Enhabit, Inc. (NYSE:EHAB) Receives Consensus Rating of “Hold” from Brokerages

Enhabit, Inc. (NYSE: EHAB - Get Free Report) has been given a consensus recommendation of "Hold" by the nine ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average

Defenseworld | 1 month ago

Enhabit Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
George Soros
George Soros Soros Fund Management LLC
1.12M $15.76M $15.44M -$324,415.8 -2.06%
AS
Alexandra Stickelman Root Financial Partners, LLC
24 $338 $331.2 -$6.8 -2.01%
CCP
Christopher C. Powers Farther Finance Advisors, LLC
1,440 $12,758.33 $19,872 $7,113.67 55.76%
JF
Jennifer Fanjiang JANA Partners Management, LP
2.09M $23.1M $28.85M $5.75M 24.9%
AM
Ashley Meredith Abel Hall, LLC
15,524 $143,131 $214,231.2 $71,100.2 49.67%

Enhabit Inc. (EHAB) FAQ

What is the stock price today?

The current price is $13.80.

On which exchange is it traded?

Enhabit Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is EHAB.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 706.91M.

Has Enhabit Inc. ever had a stock split?

No, there has never been a stock split.

Enhabit Inc. Profile

Health Care Providers & Services Industry
Healthcare Sector
Barbara Ann Jacobsmeyer CEO
NYSE Exchange
29332G102 CUSIP
US Country
10,600 Employees
- Last Dividend
- Last Split
1 Jul 2022 IPO Date

Overview

Enhabit, Inc., operating in the United States, specializes in providing a comprehensive range of home health and hospice services aimed at catering to the varying needs of patients. Established in 1998 and originally known as Encompass Health Home Health Holdings, Inc., the company underwent a rebranding in March 2022 to become Enhabit, Inc. With its headquarters located in Dallas, Texas, Enhabit has dedicated itself to enhancing the quality of life for individuals requiring home-based care and support. Through its arrayed services, Enhabit addresses the physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families, ensuring a compassionate, patient-centered approach to health care.

Products and Services

Enhabit, Inc. offers a diverse portfolio of health care services categorized under home health and hospice care:

  • Home Health Services: Enhabit's home health care encompasses a wide array of services designed to support patients in their recovery and management of chronic conditions. This includes:
    • Patient education and pain management to empower individuals in their home care.
    • Wound care, dressing changes, cardiac rehabilitation, and infusion therapy to address more direct medical needs.
    • Skilled observation and assessment services, alongside pharmaceutical administration.
    • Specialized care practices for chronic diseases and conditions such as diabetes, hypertension, arthritis, Alzheimer's disease, spinal stenosis, Parkinson's disease, and osteoporosis.
    • Disease-specific care plans tailored for patients with diabetes, congestive heart failure, post-orthopedic surgery, injury, and respiratory diseases.
    • Rehabilitation services including physical, occupational, and speech therapy.
  • Hospice Services: Focused on providing compassionate care to terminally ill patients and their families, these services include:
    • Pain and symptom management to ensure patient comfort.
    • Palliative care, dietary, and bereavement counseling services tailored to the individual's needs.
    • Social worker visits to support both emotional and logistical aspects of care.
    • Spiritual counseling to address the spiritual needs of patients and their families.

Through its comprehensive range of services, Enhabit, Inc. is committed to delivering high-quality, personalized care to patients in the comfort of their homes, addressing the full spectrum of needs that arise during the course of chronic disease management and end-of-life care.

Contact Information

Address: 6688 N. Central Expressway
Phone: 214-239-6500